Literature DB >> 27097947

Expression level of microRNA-195 in the serum of patients with gastric cancer and its relationship with the clinicopathological staging of the cancer.

Y-H Shen1, Z-B Xie, A-M Yue, Q-D Wei, H-F Zhao, H-D Yin, W Mai, X-G Zhong, S-R Huang.   

Abstract

OBJECTIVE: To study miroRNA-195 (miR-195) expression in the serum and cancer tissue of patients with gastric cancer and to investigate the relationship between its expression and clinicopathological features of gastric cancer. PATIENTS AND METHODS: Sixty-two patients with gastric cancer admitted to our institution were included in the study group, and 36 healthy persons undergoing health check-up at our institution served as control group. miR-195 expressions in the serum, gastric cancer tissue and corresponding paracancerous tissue in subjects of two groups were measured by using quantitative fluorescent real-time PCR (QF-RT-PCR), and the relationship between miR-195 and the clinicopathological features of the cancer was investigated.
RESULTS: miR-195 expression level in the serum of gastric cancer patients was significantly lower than that in the control group (p <0.05). miR-195 expression in gastric cancer tissue was also significantly lower than that in corresponding paracancerous tissue (p <0.05). The results of correlation analysis showed that low expression of miR-195 was negatively correlated with the infiltration depth, the extent of differentiation, the clinical staging and lymph node metastasis, all with statistical significance (p <0.05), but not significantly correlated with tumor locations (p >0.05).
CONCLUSIONS: Low expression of miR-195 in patients with gastric cancer may play a certain role in promoting the genesis and development of gastric cancer and it can function as a potential novel tumor marker for the early diagnosis and prognosis evaluation of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27097947

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  15 in total

1.  MicroRNA-195 inhibits human gastric cancer by directly targeting basic fibroblast growth factor.

Authors:  J Wang; L Li; M Jiang; Y Li
Journal:  Clin Transl Oncol       Date:  2017-05-12       Impact factor: 3.405

2.  MicroRNA-377-3p inhibits growth and invasion through sponging JAG1 in ovarian cancer.

Authors:  Liulin Tang; Bin Yang; Xiaolan Cao; Qin Li; Li Jiang; Dan Wang
Journal:  Genes Genomics       Date:  2019-04-30       Impact factor: 1.839

3.  Clinical value of peripheral blood microRNA detection in evaluation of SOX regimen as neoadjuvant chemotherapy for gastric cancer.

Authors:  Bibo Tan; Yong Li; Yan Di; Liqiao Fan; Qun Zhao; Qingwei Liu; Dong Wang; Nan Jia
Journal:  J Clin Lab Anal       Date:  2017-11-23       Impact factor: 2.352

4.  Preparation, characterization, and anticancer efficacy of novel cobalt oxide nanoparticles conjugated with thiosemicarbazide.

Authors:  Mahsa Jarestan; Kimia Khalatbari; Ayda Pouraei; Seyed Ataollah Sadat Shandiz; Sadaf Beigi; Mohammad Hedayati; Amitis Majlesi; Fatemeh Akbari; Ali Salehzadeh
Journal:  3 Biotech       Date:  2020-05-05       Impact factor: 2.406

5.  Expression of miR-195 is associated with chemotherapy sensitivity of cisplatin and clinical prognosis in gastric cancer.

Authors:  Rui Ye; Bo Wei; Sheng Li; Wei Liu; Juntao Liu; Luan Qiu; Xuan Wu; Zhifei Zhao; Jianxiong Li
Journal:  Oncotarget       Date:  2017-10-19

Review 6.  MicroRNAs as non-invasive diagnostic biomarkers for gastric cancer: Current insights and future perspectives.

Authors:  Alexander Link; Juozas Kupcinskas
Journal:  World J Gastroenterol       Date:  2018-08-14       Impact factor: 5.742

7.  Long Noncoding RNA SNHG12 Indicates the Prognosis and Accelerates Tumorigenesis of Diffuse Large B-Cell Lymphoma Through Sponging microR-195.

Authors:  Li-Yan Chen; Xiao-Min Zhang; Bi-Qing Han; Hai-Bin Dai
Journal:  Onco Targets Ther       Date:  2020-06-12       Impact factor: 4.147

Review 8.  MicroRNA-195: a review of its role in cancers.

Authors:  Wanpeng Yu; Xiao Liang; Xiangdong Li; Yuan Zhang; Zhenqing Sun; Ying Liu; Jianxun Wang
Journal:  Onco Targets Ther       Date:  2018-10-17       Impact factor: 4.147

9.  circZNF609 promotes the proliferation and migration of gastric cancer by sponging miR-483-3p and regulating CDK6.

Authors:  Weidong Wu; Ningxian Wei; Gang Shao; Chunnan Jiang; Shaoru Zhang; Lihui Wang
Journal:  Onco Targets Ther       Date:  2019-10-04       Impact factor: 4.147

10.  Resveratrol inhibits the growth of gastric cancer via the Wnt/β-catenin pathway.

Authors:  Hui Dai; Hou-Bo Deng; Ya-Hong Wang; Jia-Juan Guo
Journal:  Oncol Lett       Date:  2018-05-22       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.